Hanjoon Alex Kim - 21 Mar 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Chief Financial Officer
Signature
/s/ Hanjoon Alex Kim by Tomone Tanaka, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
21 Mar 2025
Net transactions value
$0
Form type
4
Filing time
24 Mar 2025, 18:37:31 UTC
Previous filing
21 May 2024
Next filing
08 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +338,333 +61% $0.000000 892,098 21 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to Buy) Award $0 +507,500 $0.000000 507,500 21 Mar 2025 Common Stock 507,500 $1.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") that vest over four years, with 1/16th of the RSUs vesting on May 20, 2025 and the remaining RSUs vesting in equally quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2 Includes an aggregate of 9,364 shares of common stock acquired by the reporting person on May 31, 2024 and November 29, 2024 under the Issuer's Employee Stock Purchase Plan.
F3 The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2025, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.